Kodiak Sciences ($KOD) Jumps 178% After Eye Drug Matches Regeneron's Eylea in Late-Stage Trial

Kodiak Sciences ($KOD) jumped 178% on Monday, from about $30 to $88, after its eye drug matched Regeneron's ($REGN) blockbuster Eylea in a late-stage trial.
The post says one Phase 3 readout nearly tripled the company in a day, calling it the binary math of clinical-stage biotech: a single result can be worth more than years of sales, and it runs both ways. It adds that Monday paid a triple, while a failed readout is a trap door.